Alto Neuroscience, Inc.
ANRO NYSE
SEC CIK 1999480
Follow Alto Neuroscience
Weekly email: filings, results
Net income
−$25.1M
−77.2% vs same quarter last year
EPS, diluted
−$0.54
−3.8% vs same quarter last year
Operating cash flow
−$20.8M
−109.3% vs same quarter last year
Operating income
−$27.2M
−82.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$63.2M |
| FY24 | −$61.4M |
| FY23 | −$36.3M |
| FY22 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$51.8M |
| FY24 | −$49.5M |
| FY23 | −$33.9M |
| FY22 | - |